-Preventing metabolic disease
Sigrid Therapeutics AB (Sigrid) is a Swedish clinical-stage biotechnology company whose lead product candidate is SiPore15TM, a precisely engineered, orally ingested material acting locally in the gut. The material is protected by filed IP and produced to cGMP standards. SiPore15TM is under development as a first-in-class medical device targeting prediabetics and newly diagnosed type two diabetics. First in Man data indicates that SiPore15TM has a favorable safety profile and significant effects on blood sugar, blood lipids and body fat composition. SiPore15TM is the lead product candidate based on Sigrid’s proprietary platform technology SiPoreTM. Solutions based on SiPoreTM have the potential to become breakthrough therapies for a range of preventable metabolic disorders and diseases with high unmet clinical need.